19
Participants
Start Date
December 31, 2006
Primary Completion Date
March 31, 2008
Study Completion Date
March 31, 2008
volociximab
Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.
Site Reference ID/Investigator# 70380, Greenville
Site Reference ID/Investigator# 70359, St Louis
Site Reference ID/Investigator# 70377, Dallas
Site Reference ID/Investigator# 70375, Aurora
Site Reference ID/Investigator# 70357, Scottsdale
Site Reference ID/Investigator# 70356, La Jolla
Site Reference ID/Investigator# 70376, Boston